Mint Sirisawad
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- Histone Deacetylase Inhibitors Research 15
- Protein Degradation and Inhibitors 10
- Cell death mechanisms and regulation 5
- Ubiquitin and proteasome pathways 5
- Genetics 12
- Chronic Lymphocytic Leukemia Research 12
- Co-authors
- Joseph J. Buggy (11 shared papers)Erik Verner (2 shared papers)Richard A. Miller (16 shared papers)Betty Chang (7 shared papers)David Loury (3 shared papers)Lee Honigberg (2 shared papers)Ashley M. Smith (2 shared papers)Douglas H. Thamm (1 shared paper)
- Journals
- Blood (12 papers)Molecular Cancer Therapeutics (5 papers)Cancer Research (5 papers)Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)
- Partner nations
- United StatesChinaBelgium
In The Last Decade
Mint Sirisawad
38 papers receiving 2.3k citations
Mint Sirisawad's Hit Papers
Peers
Comparison fields: 5 of 92
- Genetics 956
- Pathology and Forensic Medicine 767
- Hematology 334
- Oncology 695
- Immunology 416
Countries citing papers authored by Mint Sirisawad
This map shows the geographic impact of Mint Sirisawad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mint Sirisawad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mint Sirisawad more than expected).
Fields of papers citing papers by Mint Sirisawad
This network shows the impact of papers produced by Mint Sirisawad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mint Sirisawad. The network helps show where Mint Sirisawad may publish in the future.
Co-authors
The 25 scholars most cited alongside Mint Sirisawad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Hit paper breakdown → | 2010 | 1160 |
| 2 | 2008 | 363 | |
| 3 | 2007 | 180 | |
| 4 | 2009 | 82 | |
| 5 | 2015 | 73 | |
| 6 | 2005 | 58 | |
| 7 | 2014 | 53 | |
| 8 | 2006 | 50 | |
| 9 | 2017 | 45 | |
| 10 | 2015 | 39 | |
| 11 | The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. | 2016 | 37 |
| 12 | 2005 | 35 | |
| 13 | 2006 | 34 | |
| 14 | 2010 | 28 | |
| 15 | 2005 | 26 | |
| 16 | 2005 | 19 | |
| 17 | 2006 | 18 | |
| 18 | 2012 | 16 | |
| 19 | 2008 | 14 | |
| 20 | 2006 | 13 |
About Mint Sirisawad
Mint Sirisawad is a scholar working on Molecular Biology, Genetics, Oncology, Pathology and Forensic Medicine and Immunology, having authored 38 papers that have together received 2.4k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (15 papers), Chronic Lymphocytic Leukemia Research (12 papers), Protein Degradation and Inhibitors (10 papers), Lymphoma Diagnosis and Treatment (6 papers), Cell death mechanisms and regulation (5 papers), Ubiquitin and proteasome pathways (5 papers), Viral-associated cancers and disorders (3 papers) and Porphyrin and Phthalocyanine Chemistry (3 papers). The work is most often cited by research in Genetics (956 citations), Pathology and Forensic Medicine (767 citations), Hematology (334 citations), Oncology (695 citations) and Immunology (416 citations). Mint Sirisawad has collaborated with scholars based in United States, China and Belgium. Frequent co-authors include Joseph J. Buggy, Erik Verner, Richard A. Miller, Betty Chang, David Loury, Lee Honigberg, Ashley M. Smith, Douglas H. Thamm, Zhengying Pan and Sriram Balasubramanian. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Cancer Research, Clinical Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.